Skip to main content

Table 3 Plasma levels of LCN2, MMP9, and MMP9/LCN2 complex in different types of nAMD patients and controls

From: Plasma level of lipocalin 2 is increased in neovascular age-related macular degeneration patients, particularly those with macular fibrosis

Variable Control (N = 43, Mean ± SD) CNV (N = 108, Mean ± SD) RAP (N = 32, Mean ± SD) PCV (N = 23, Mean ± SD) p value
Age 73.4 ± 8.9 78.9 ± 7.8† 80.7 ± 8.7† 71.6 ± 8.9  
LCN2 (ng/ml) 153.24 ± 49.55 186.60 ± 71.57* 176.08 ± 82.70 168.36 ± 70.68 0.108a
MMP9 (ng/ml) 124.16 ± 63.12 114.42 ± 58.93 111.18 ± 96.94 126.40 ± 65.09 0.301a
MMP9/LCN2 (ng/ml) 188.38 ± 45.12 176.51 ± 53.35 181.69 ± 66.07 196.29 ± 66.05 0.370b
  1. CNV choroidal neovascularisation, RAP retinal angiomatous proliferation, PCV polypoidal choroidal vasculopathy
  2. †P < 0.05 compared to controls
  3. *P = 0.006 compared to controls in univariate analysis
  4. aKruskal-Wallis one-way analysis of variance on log transformed data
  5. bOne-way ANOVA
Back to article page

Immunity & Ageing

ISSN: 1742-4933

Contact us